<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; INCY</title>
	<atom:link href="http://www.stockbloghub.com/tag/incy/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(LLY) Eli Lilly Provides Research and Development Update</title>
		<link>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330</link>
		<comments>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330#comments</comments>
		<pubDate>Tue, 05 Jul 2011 16:34:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78330</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&#38;D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products. About $7 billion of revenues will be lost to generic competition due to the loss of exclusivity of products like Zyprexa, Cymbalta, Evista, and Gemzar. Pipeline to Drive Long-Term Growth Eli Lilly intends to continue spending significantly on its pipeline. The company expects to spend about 25% of revenues on its R&#38;D efforts.  Eli Lilly currently has about 70 candidates in its pipeline including 33 candidates in phase II and III stages of development. The company expects to launch several candidates through 2017 and is on track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486</link>
		<comments>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486#comments</comments>
		<pubDate>Thu, 16 Jun 2011 14:25:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76486</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Incyte Corporation (INCY) with a target price of $18.00. Incyte is a Wilmington, Delaware-based drug discovery and development company with a focus on oral compounds to treat HIV, inflammation and cancer. The company&#8217;s lead compound is INCB18424, an oral janus-associated kinase (JAK) antagonist. Incyte is currently seeking US approval of INCB18424 for treating patients suffering from myelofibrosis (MF), a rare bone marrow disorder. Incyte submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for INCB424 earlier in the month. The company expects to launch INCB18424 for MF in the US later this year (assuming that the FDA reviews the application on a priority basis). We believe that if INCB 18424 is approved and subsequently marketed successfully for MF ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/incy-incyte-corporation-analyst-maintains-neutral-on-shares/76486/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Posts Solid First Quarter Sales</title>
		<link>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906</link>
		<comments>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:54:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71906</guid>
		<description><![CDATA[Novartis (NVS) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windfall sales of H1N1 flu vaccines that were not to be repeated in the current quarter. First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/nvs-novartis-posts-solid-first-quarter-sales/71906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Loss Smaller Than Forecast &#8211; Revenues Strong</title>
		<link>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408</link>
		<comments>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408#comments</comments>
		<pubDate>Mon, 15 Nov 2010 22:14:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59408</guid>
		<description><![CDATA[Incyte Corporation (INCY) suffered a loss of 26 cents per share in the third quarter of 2010. Loss in the reported quarter was narrower than the Zacks Consensus Estimate of a loss of 33 cents and the year-ago loss (excluding special items) of 39 cents per share. The strong performance in the quarter was attributable to a surge in revenues. Total revenues in the reported quarter jumped to $16.9 million from $939,000 in the year-ago quarter. Revenues were boosted by the receipt of $16.7 million in milestone payments from partners Novartis (NVS) and Eli Lilly &#38; Co. (LLY).  Revenues were in line with the Zacks Consensus Estimate. Total cost and expenses in the reported quarter climbed 19.8% to $38.9 million. Both research and development (R&#38;D) expenses (up 15.4%) and selling, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/incy-incyte-loss-smaller-than-forecast-revenues-strong/59408/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation&#8217;s Earnings Report Beats &#8211; Firm Raises Guidance</title>
		<link>http://www.stockbloghub.com/2010/05/11/incy-incyte-corporations-earnings-report-beats-firm-raises-guidance/36806</link>
		<comments>http://www.stockbloghub.com/2010/05/11/incy-incyte-corporations-earnings-report-beats-firm-raises-guidance/36806#comments</comments>
		<pubDate>Tue, 11 May 2010 21:43:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36806</guid>
		<description><![CDATA[Incyte Corporation’s (INCY) first quarter fiscal 2010 loss per share came in at 30 cents compared to a loss of 41 cents reported in the year-ago period. However, excluding non-cash charge related to notes redemption, the company reported a loss of 27 cents per share, better than the Zacks Consensus Estimate of a loss of 31 cents. Incyte reported revenues of $17.3 million compared to $0.7 million in the first quarter of 2009. The collaboration agreement with Novartis (NVS) and Eli Lilly (LLY) primarily led to the increase in revenues. In addition to releasing quarterly results, Incyte provided an update on its pipeline candidates. In 2009, the company entered into a collaboration and license agreement with Novartis for two of its pipeline candidates – INCB18424, an oral JAK1/JAK2 inhibitor and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/11/incy-incyte-corporations-earnings-report-beats-firm-raises-guidance/36806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SIGA) Why the Straightforward Approach is Often the Most Profitable</title>
		<link>http://www.stockbloghub.com/2010/04/07/siga-why-the-straightforward-approach-is-often-the-most-profitable/33005</link>
		<comments>http://www.stockbloghub.com/2010/04/07/siga-why-the-straightforward-approach-is-often-the-most-profitable/33005#comments</comments>
		<pubDate>Thu, 08 Apr 2010 00:16:16 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[SIGA]]></category>
		<category><![CDATA[SIGA Technologies Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33005</guid>
		<description><![CDATA[“Don’t be a knucklehead.” This was the sage advice of John Roque, Chief Technical Strategist at WJB Capital in a note to clients earlier this week. He was advising them against trying to short strong markets or buy weak ones. Such a simple, clear message. For years, an abundance of confidence led me to believe that I was so good at picking stocks, I could do it at market tops or bottoms and bag a winner every time. I don’t do that anymore. Although I’m a contrarian investor and often go against the grain, there’s a famous expression on Wall Street: “Don’t try to catch a falling knife.” In other words, don’t fight the prevailing trend. If I believe a stock is set to fall (whether because it’s overvalued, the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/07/siga-why-the-straightforward-approach-is-often-the-most-profitable/33005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly Misses Earnings Reports by a Penny</title>
		<link>http://www.stockbloghub.com/2010/01/28/lly-eli-lilly-misses-earnings-reports-by-a-penny/26308</link>
		<comments>http://www.stockbloghub.com/2010/01/28/lly-eli-lilly-misses-earnings-reports-by-a-penny/26308#comments</comments>
		<pubDate>Thu, 28 Jan 2010 21:09:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26308</guid>
		<description><![CDATA[This morning, Eli Lilly (LLY) reported fourth quarter and fiscal 2009 results. The company reported earnings per share (EPS) of 83 cents, compared to a loss of $3.31 in the corresponding period last year. However, after making adjustments for certain items, Lilly’s EPS came in at 91 cents, which missed the Zacks Consensus Estimate by a penny and was lower than the year ago quarter’s $1.02. Revenues recorded a 14% year-over-year increase to $5.93 billion driven by an increase in volume, prices as well as a favorable impact of foreign exchange. For the full year, Lilly reported a 7% growth in revenues, which came in at $21.8 billion driven by increased volume and prices, partially offset by foreign exchange rates. EPS of $4.42 increased 16% compared to last year. During ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/lly-eli-lilly-misses-earnings-reports-by-a-penny/26308/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Collaborates with GenVec on Hearing Loss Treatments</title>
		<link>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401</link>
		<comments>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[GenVec Inc]]></category>
		<category><![CDATA[GNVC]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25401</guid>
		<description><![CDATA[Recently, Novartis (NVS) entered into a collaboration with GenVec (GNVC) for the development of treatments for hearing loss and balance disorders. Earlier, preclinical results have found strong potential in GenVec&#8217;s adenovector technology for the restoration of hearing and balance functions. Per the agreement, Novartis has acquired worldwide rights to the program, for which it has paid $5 million upfront. GenVec is also eligible to receive up to $213.6 million in the form of milestone payments and royalties on the sale of the drug. In addition, Novartis has purchased shares of GenVec worth $2 million. It will also provide funding to GenVec for conducting research programs for the development of additional adenovectors for hearing loss. Novartis is looking at strengthening its pipeline to compensate for the loss of revenues once several ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KERX) Healthcare Stock Watch: Short List of Booming (and Busting) Companies</title>
		<link>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406</link>
		<comments>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:11:08 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[KERX]]></category>
		<category><![CDATA[Keryx Biopharmaceuticals Inc]]></category>
		<category><![CDATA[QCOR]]></category>
		<category><![CDATA[Questcor Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25406</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 20, 2010: Issue #1179 On my way out to San Francisco last week, I never thought that I’d compare the biggest healthcare conference of the year to the dating scene. But that’s the overall vibe that I took away from the JP Morgan Healthcare Conference. The investors I spoke with reminded me of jilted lovers – eager to get back on the market, but scared to get hurt again. Rather than checking out the eligible candidates on Match.com, though, healthcare investors spend their time poring over companies’ balance sheets and drug pipelines. And so it was in San Francisco. Everyone wanted to be optimistic, but that optimism was only expressed in private conversations. When I saw the same investors in front of companies’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/kerx-healthcare-stock-watch-short-list-of-booming-and-busting-companies/25406/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Enters Deal With Eli Lilly</title>
		<link>http://www.stockbloghub.com/2009/12/22/incy-incyte-enters-deal-with-eli-lilly/23458</link>
		<comments>http://www.stockbloghub.com/2009/12/22/incy-incyte-enters-deal-with-eli-lilly/23458#comments</comments>
		<pubDate>Wed, 23 Dec 2009 00:29:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23458</guid>
		<description><![CDATA[It’s raining good news for Incyte (INCY), which entered into a deal with Eli Lilly (LLY) regarding one of its pipeline candidates. The two companies have entered into a worldwide license and collaboration agreement related to the development and commercialization of Incyte&#8217;s oral JAK1/JAK2 inhibitor, INCB28050, and certain other follow on drugs for inflammatory and autoimmune diseases. INCB28050 is currently being studied in a phase II trial for the treatment of rheumatoid arthritis (RA). As per the agreement, while Lilly will receive worldwide rights to the compound, Incyte has retained its co-development and co-promotion rights. Under the deal, Incyte will receive an initial payment of $90 million as well as another $665 million in the form of milestone payments. In addition, the company is also eligible to receive tiered, double-digit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/incy-incyte-enters-deal-with-eli-lilly/23458/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Corporation Enters Into License Agreement With Novartis</title>
		<link>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550</link>
		<comments>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:46:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[MF]]></category>
		<category><![CDATA[MF Global Ltd]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21550</guid>
		<description><![CDATA[Incyte Corporation (INCY) entered into a collaboration and license agreement with Novartis AG (NVS) regarding two of its pipeline candidates – INCB18424, an oral JAK1/JAK2 inhibitor and INCB28060, an oral cMET inhibitor. While the former is currently being studied in a phase III clinical trial for myelofibrosis (MF), the latter is yet to enter phase I trial as a potential treatment for multiple cancers. Along with MF, INCB18424 is in phase II trial for patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) As per the terms of the agreement, Incyte will retain exclusive rights for the development and potential commercialization of INCB18424 in the US whereas outside the US, Novartis will have responsibility for its future development and commercialization in all indications. In addition, Novartis will also be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/incy-incyte-corporation-enters-into-license-agreement-with-novartis/21550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(INCY) Incyte Marginally Beats Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/09/incyte-marginally-beats-earnings-estimates/20025</link>
		<comments>http://www.stockbloghub.com/2009/11/09/incyte-marginally-beats-earnings-estimates/20025#comments</comments>
		<pubDate>Mon, 09 Nov 2009 23:06:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20025</guid>
		<description><![CDATA[Incyte&#8216;s (INCY) third-quarter loss per share came was 39 cents, marginally better than the Zacks Consensus Estimate for a loss of 41 cents. In the year-ago quarter, the company&#8217;s loss was 48 cents. INCY reported revenues of $0.9 million, compared to $1.1 million last year. We believe the current investor focus is more on the developments of the company&#8217;s portfolio rather than the financials. In addition to releasing the third-quarter results, Incyte provided an update on its pipeline candidates. The most advanced pipeline candidate, INCB18424, is being developed under the company&#8217;s Janus Kinase Inhibitor Program. The oral formulation of the compound is undergoing phase III trials for the treatment of myelofibrosis, Polycythemia Vera and Essential Thrombocythemia. Patient enrollment for the trial is going on in both the US and Europe. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/incyte-marginally-beats-earnings-estimates/20025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

